Olanzapine versus haloperidol for treatment of delirium in patients with advanced cancer : a phase iii randomized clinical trial by van der Vorst, M et al.
Olanzapine Versus Haloperidol for Treatment of Delirium in
Patients with Advanced Cancer: A Phase III Randomized
Clinical Trial
MAURICE J.D.L. VAN DER VORST ,a,e,† ELISABETH C.W. NEEFJES,a,† MANON S.A. BODDAERT,f BEA A.T.T. VERDEGAAL,a AART BEEKER,g
SASKIA C.C. TEUNISSEN,h,i AARTJAN T.F. BEEKMAN,b JANNEKE A. WILSCHUT,c JOHANNES BERKHOF,c WOUTER W.A. ZUURMOND,d,j
HENK M.W. VERHEUL a
Departments of aMedical Oncology, Cancer Center Amsterdam, bPsychiatry, cEpidemiology and Biostatistics, and dAnesthesiology,
Amsterdam UMC, Vrije Universiteit, Amsterdam, The Netherlands; eDepartment of Internal Medicine, Rijnstate Hospital, Arnhem,
The Netherlands; fNetherlands Comprehensive Cancer Organisation (IKNL), Utrecht, The Netherlands; gDepartment of Internal
Medicine, Spaarne Gasthuis, Hoofddorp, The Netherlands; hDepartment of General Practice, Julius Center for Health Sciences and
Primary Care, University Medical Center Utrecht, Utrecht, The Netherlands; iAcademic Hospice Demeter, De Bilt, The Netherlands;
jHospice Kuria, Amsterdam, The Netherlands
†Contributed equally.
Disclosures of potential conflicts of interest may be found at the end of this article.
Key Words. Delirium • Advanced cancer • Haloperidol • Olanzapine • Efficacy • Safety • Phase III
ABSTRACT
Background. Treatment of delirium often includes haloperi-
dol. Second-generation antipsychotics like olanzapine have
emerged as an alternative with possibly fewer side effects.
The aim of this multicenter, phase III, randomized clinical trial
was to compare the efficacy and tolerability of olanzapine
with haloperidol for the treatment of delirium in hospitalized
patients with advanced cancer.
Materials and Methods. Eligible adult patients (≥18 years)
with advanced cancer and delirium (Delirium Rating Scale-
Revised-98 [DRS-R-98] total score ≥17.75) were randomized
1:1 to receive either haloperidol or olanzapine (age-adjusted,
titratable doses). Primary endpoint was delirium response
rate (DRR), defined as number of patients with DRS-R-98
severity score <15.25 and ≥4.5 points reduction. Secondary
endpoints included time to response (TTR), tolerability, and
delirium-related distress.
Results. Between January 2011 and June 2016, 98 patients
were included in the intention-to-treat analysis. DRR was 45%
(95% confidence interval [CI], 31–59) for olanzapine and 57%
(95% CI, 43–71) for haloperidol (Δ DRR −12%; odds ratio
[OR], 0.61; 95% CI, 0.2–1.4; p = .23). Mean TTR was 4.5 days
(95% CI, 3.2–5.9 days) for olanzapine and 2.8 days (95% CI,
1.9–3.7 days; p = .18) for haloperidol. Grade ≥3 treatment-
related adverse events occurred in 5 patients (10.2%) and
10 patients (20.4%) in the olanzapine and haloperidol arm,
respectively. Distress rates were similar in both groups. The
study was terminated early because of futility.
Conclusion. Delirium treatment with olanzapine in hospitalized
patients with advanced cancer did not result in improvement
of DRR or TTR compared with haloperidol. Clinical trial identifi-
cation number. NCT01539733. Dutch Trial Register. NTR2559.
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Implications for Practice: Guidelines recommend that pharmacological interventions for delirium treatment in adults with
cancer should be limited to patients who have distressing delirium symptoms. It was suggested that atypical antipsychotics,
such as olanzapine, outperform haloperidol in efficacy and safety. However, collective data comparing the efficacy and
safety of typical versus atypical antipsychotics in patients with cancer are limited. If targeted and judicious use of antipsy-
chotics is considered for the treatment of delirium in patients with advanced cancer, this study demonstrated that there
was no statistically significant difference in response to haloperidol or olanzapine. Olanzapine showed an overall better
safety profile compared with haloperidol, although this difference was not statistically significant.
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INTRODUCTION
Delirium is a common, complex neuropsychiatric disorder
with a high prevalence among hospitalized patients with
advanced cancer [1, 2]. This medical condition is character-
ized by changes in attention, awareness, and cognition,
which develop over a short period of time and tend to fluctu-
ate in severity during the course of a day [3]. Delirium is
associated with high morbidity and increased mortality [4,
5]; it causes significant distress in patients and their care-
givers and interferes with symptom assessment and decision
making [6, 7]. Therefore, early recognition and adequate
management of delirium is of utmost importance in the care
of hospitalized patients with advanced cancer.
New guidelines recommend that the use of pharmaco-
logical interventions in the management of delirium should
be limited to patients with distressing symptoms (such as
agitation, anxiety, or perceptual disturbances) or if there are
safety concerns in which the patient is a potential risk to
themselves or others [8, 9]. In general, haloperidol, a typical
or first-generation antipsychotic, is recommended as the first
line pharmacological option [10, 11]. A recently performed
systematic review and meta-analysis of 15 randomized clini-
cal trials suggested that atypical or second-generation anti-
psychotics, including olanzapine, have a benefit with regard
to efficacy and safety compared with haloperidol [12]. Pooled
atypical antipsychotics were associated with a shorter time
to response (TTR; standard mean difference [SMD], −0.27)
and a lower incidence (risk ratio [RR], 0.3) of extrapyramidal
symptoms (EPS). However, most of the included studies were
single center with small sample sizes, heterogeneous study
populations, and at risk of bias.
Recently, a Cochrane systematic review included nine trials
with 727 participants, assessing antipsychotics for delirium treat-
ment in non-ICU patients [9]. Seven trials included a comparison
of a typical to an atypical antipsychotic drug or placebo, including
three studies evaluating patients with advanced cancer [13–15].
Pooled analysis showed no significant difference in delirium
severity (SMD −0.17; 95% confidence interval [CI], −0.4 to 0.02;
seven studies; 542 participants), overall delirium resolution (RR,
1.1; 95% CI, 0.8–1.5; five studies; 349 participants), overall mor-
tality (RR, 1.7; 95% CI, 0.8–3.5; four studies; 342 participants), or
increased risk of EPS (RR, 12.2; 95% CI, 0.55–270; two studies;
198 participants) with atypical antipsychotics comparedwith typ-
ical antipsychotics. There was no evidence to support or refute
the suggestion that antipsychotics shorten the course of delirium
in hospitalized patients. However, the results were assessed as
(very) low evidence (downgraded because of risk of bias, incon-
sistency, and/or imprecision). Moreover, important clinical end-
points, like duration of delirium, health-related quality of life,
and cardiac arrhythmia, were not reported for any trial compar-
ing typical versus atypical antipsychotics.
Taken together, the efficacy and safety of pharmacologi-
cal interventions for the treatment of delirium in patients
with cancer is controversial. Effective and safe strategies for
the management of delirium remain an unmet clinical need.
Atypical antipsychotics may be an effective and safe alter-
native to haloperidol. Therefore, we conducted a multicen-
ter, phase III randomized clinical trial (RCT) to compare the
efficacy and tolerability of age-adjusted and titratable doses
of olanzapine versus haloperidol for the treatment of delir-
ium in hospitalized patients with advanced cancer.
SUBJECTS, MATERIALS, AND METHODS
Study Design
This multicenter, randomized controlled, phase III trial
(NCT01539733) was conducted at five sites (1 university
cancer center, 2 teaching hospitals, 2 high-care hospices) in
The Netherlands between January 2011 and July 2016. At
the time of their admission, patients and/or their legal rep-
resentatives were asked for written informed consent to
participate in this study in case the patient was diagnosed
with delirium during hospitalization. The method for con-
cealment of allocation was by enclosing assignments in
sequentially numbered, opaque, sealed envelopes provided
by an independent third party (university medical center
pharmacist). The envelopes were opened sequentially, and
only after the envelope had been irreversibly assigned to
the participant. The study staff assessing the effect of anti-
psychotic treatment was blinded to the participant’s treat-
ment group for the entire duration of the study. The clinical
staff administering the study medication and the patient
being treated were not blinded. The study was conducted
according to good clinical practice guidelines, the Declara-
tion of Helsinki, and local laws and was approved by the
institutional review boards of each participating study site.
Patients
Eligible patients were ≥18 years of age with advanced can-
cer, were admitted to a medical oncology ward or high-care
hospice facility, spoke the Dutch language fluently, and
were diagnosed with delirium. Exclusion criteria included
diagnosis of glaucoma, Parkinson’s disease, dementia, psy-
chiatric disorders interfering with delirium assessment, his-
tory of neuroleptic malignant syndrome or convulsions,
delirium due to substance withdrawal, or cardiac conduc-
tion abnormalities (prolonged QTc interval of >500 msec on
the electrocardiogram [ECG]). Patients being treated with
other neuroleptic medication or lithium were also excluded
from entering the study, because of the high probability of
interactions (QTc prolongation, EPS, tardive dyskinesia, neu-
roleptic malignant syndrome etc.).
Procedures
Newly admitted patients were screened for delirium by the
attending nurse using the delirium observation scale (DOS)
on set days (Mondays and Thursdays) during each nursing shift
(day, evening, night) or whenever delirium was suspected by
the nursing or medical staff. The DOS is a 13-item scale based
on the Diagnostic and Statistical Manual of Mental Disorders
fourth edition (DSM-IV) criteria for delirium, designed to be
completed by a nurse [16]. The DOS is an accurate screening
scale for delirium in patients with advanced cancer [17]. The
range of the total DOS score is 0–13; a total score of ≥3 indi-
cates delirium. Patients with DOS score ≥3 were assessed on
Delirium Rating Scale-R-98 (DRS-R-98) by a blinded assessor to
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confirm the diagnosis of delirium. The DRS-R-98 has 16 items,
13 of which assess the severity of symptoms, and 3 items are of
diagnostic significance [18]. The rating is applicable to the pre-
ceding 24 hours. Each severity item’s rating levels are anchored
with descriptions appropriate to that particular symptom. The
severity ratings range from 0 (no impairment) to 3 (severe
impairment), and a severity score of ≥15.25 or a total score of
≥17.75 is indicative of delirium; higher scores indicate higher
severity of delirium. Delirium is considered cleared if the sever-
ity score is <15.25 with a decline of at least 4.5 points (d = 0.8)
in the total score [18]. Site initiation involved training of the
clinical and study staff for standardized assessment of DOS and
DRS-R-98 scores (performed by M.V. and E.N.).
Once delirium was diagnosed, potential precipitating factors
for delirium, including changes in dose or type of opioids
(<48 hours before diagnosis of delirium), dehydration, infection,
intracranial malignancy, infection, and metabolic imbalances,
were identified and scored (yes or no) by a comprehensive
assessment. Delirium was categorized according to motor sub-
type (hypoactive, hyperactive, or mixed), based on DRS-R-98
item 7 (motor agitation) and item 8 (motor retardation). We also
determined the predominance of certain “psychomotor fea-
tures” by clinical observation. The hypoactive subtype is charac-
terized by reduced alertness, sedation, and reduction of motor
activity. The hyperactive form is associated with hypervigilance,
overt psychotic features (e.g., hallucinations, delusions), and agi-
tation. The mixed subtype has overlapping features of the
hypoactive and hyperactive subtypes. All patients received tai-
lored interventions targeted at the underlying causes of delirium,
and appropriate nonpharmacological measures were taken
according to clinical practice guidelines [8, 10, 11]. Subsequently,
all patients were randomized in a 1:1 ratio to receive haloperidol
orally (PO) or subcutaneously (SC), or olanzapine PO or intramus-
cularly (IM). Dosing of antipsychotics was age adjusted and based
on clinical practice guidelines [10, 11].
Patients <75 years of age assigned to haloperidol started
with a loading dose of 1 mg. DOS scores were determined
every 40 minutes thereafter. If the DOS score was ≥3, subse-
quent doses were increased by 1 mg up to a maximum dose
of 20 mg PO or 10 mg SC on day 1 (supplemental online
Table 1). Patients <75 years of age assigned to olanzapine
started with a loading dose of 5 mg. DOS scores were deter-
mined every 2 hours thereafter. If the DOS score was ≥3, sub-
sequent doses were increased to a maximum dose of 20 mg
PO or IM (supplemental online Table 2). The loading, titration,
and maximum doses of both haloperidol and olanzapine were
halved for patients ≥75 years of age.
If the DOS score was <3, resolution of delirium was con-
firmed by DRS-R-98 assessment. Maintenance dose of halo-
peridol or olanzapine was one-half of the total dose of the
study drug administered during the first 24 h after initiation
and divided in 1 or 2 doses. On days 2, 3, 4, and 7, DRS-R-98
assessment was repeated. If the DRS-R-98 severity score was
≥15.25, maintenance doses of haloperidol and olanzapine
were adjusted (supplemental online Table 1 and 2).
Treatment with antipsychotics was discontinued if the max-
imum daily dose of the study drug was reached without resolu-
tion of delirium or if serious (grade ≥3) treatment-related
adverse events (TRAEs) occurred. TRAEs, including somnolence,
dizziness, and EPS (including tremors and muscle stiffness),
were monitored and graded daily according to the Common
Terminology Criteria for Adverse Events (CTCAE) version 4.03
[19] by the study staff. ECG was performed before initiation
of the study drug and on day 2. If QTc prolongation (>500
msec) occurred, treatment with the study drug was also dis-
continued. Administration of the benzodiazepine receptor
agonist lorazepam PO or intravenously (IV) was allowed if
the patient was deemed to require immediate intervention
for safety or distress by the clinical staff. There was no pre-
determined dose schedule for the administration of PO or IV
Randomized (n = 100)
50 allocated to olanzapine
• 49 received at least one dose of
allocated intervention*
9 discontinued treatment
• 6 due to death
• 3 due to noncompliance
50 allocated to haloperidol
• 49 received at least one dose of
allocated intervention*
8 discontinued treatment
• 7 due to death
• 1 due to noncompliance
Analyzed
Intention-to-treat n = 49
Per protocol n = 40
Analyzed
Intention-to-treat n = 49
Per protocol n = 41
Figure 1. CONSORT diagram. *Data were missing from one patient in each treatment arm.
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lorazepam. For optimal results, dose, frequency of adminis-
tration, and duration of therapy with lorazepam were indi-
vidualized according to patient response.
Patients who had recovered from delirium were asked to
complete the Delirium Experience Questionnaire (DEQ). The
DEQ is a face-valid brief questionnaire asking six questions
(three questions, yes or no; two questions, 0–4 numerical
rating scale with 0 = not at all and 4 = extremely; one ques-
tion, qualitative assessment) to assess recall of the delirium
experience and the degree of distress related to the delirium
episode [6]. Spouses and/or caregivers and attending nurses
were also asked to complete the DEQ to assess the level of
caregiver distress.
Endpoint and Statistical Analysis
The primary endpoint was delirium response rate (DRR) on
days 1–7 after randomization as defined by DRS-R-98 assess-
ment (severity score <15.25; decline ≥4.5 points total score).
Secondary endpoints included TTR, defined as the time from
randomization to resolution of delirium (number of days);
TRAEs according to CTCAE version 4.03; and delirium-related
distress for patients and their caregivers assessed by DEQ.
An exploratory analysis of DRR was conducted for each
motor subtype of delirium.
Assuming a 25% improvement in DRR (from 50% to 75%)
with olanzapine compared with haloperidol [20], with α set to
5% and power to 90% and an expected dropout rate of 15%,
the total sample size was 100 evaluable patients per treat-
ment arm. DRR was compared between the two randomized
groups by chi-square tests and by calculating the 95% CI of
the difference of the proportions in both the intention-to-
treat (ITT) and the per protocol (PP) cohort (i.e., all patients
who completed antipsychotic treatment). TTR outcomes in
the ITT cohort were compared between the two treatment
groups in the ITT by using stratified log-rank tests and were
plotted in a Kaplan-Meier curve. TRAEs and DEQ scores were
analyzed in an explorative or descriptive manner. All reported
p values are two sided.
Futility analysis was conducted after 50% (n = 100) of
the patients required for DRR analysis was included. The
threshold for futility was set at a conditional power of 10%,
which is usually applied as a stopping rule [21]. All analyses
were conducted by an independent statistician using IBM
SPSS statistics version 22 (IBM, Chicago, IL).
RESULTS
Between January 1, 2011, and June 15, 2016, a total
100 patients were randomly assigned: 50 patients per treat-
ment arm (Fig. 1). Data were missing from one patient in
each treatment arm. Ninety-eight patients (49 patients per
treatment arm) were included in the ITT cohort; 81 patients
(40 in the olanzapine arm, and 41 in the haloperidol arm)
were in the PP cohort.
Table 1 describes the baseline characteristics of the ITT
population, which were generally well balanced between
the two arms. The majority of the patients were male
(69.4%), with a mean age of approximately 69 years in both
treatment groups. Mean DRS-R-98 total score at randomiza-
tion was approximately 23 in both arms. Median number of
precipitating factors for delirium was 2 (interquartile range
[IQR], 1–3; range, 0–5). Most patients (n = 89; 91%) were
admitted to a hospital ward. Reason for hospitalization was
an emergency admission in 84.7% of the patients.
Efficacy
Median olanzapine dose was 8.8 mg (IQR, 5.0–15.0 mg) on
day 1, 5.0 mg (IQR, 0.0–10.0 mg) on day 2, and 5.0 mg (IQR,
1.9–10.0 mg) at the end of study. For haloperidol, median
dose was 2.5 mg (IQR, 1.0–4.8 mg) on day 1, 1.3 mg
(IQR, 0.5–2.9 mg) on day 2, and 1.8 mg (IQR, 0.5–2.8 mg) at
the end of study.
In the ITT cohort, DRR was 45% (95% CI, 31–59) for
olanzapine and 57% (95% CI, 43–71) for haloperidol (ΔDRR
−12%; odds ratio [OR], 0.61; 95% CI, 0.2–1.4; p = .23). DRR
was 56% for olanzapine (95% CI, 41–72) and 68% (95% CI,
54–83) for haloperidol (ΔDRR −12%; OR, 0.61; 95% CI,
0.2–1.5; p = .27) in the PP cohort. Mean TTR in the olanzapine
arm was 4.5 days (95% CI, 3.2–5.9), and it was 2.8 days (95%
CI, 1.9–3.7; p = .18) in the haloperidol arm. (Fig. 2). Explor-
atory analysis did not demonstrate any significant benefit of
Table 1. Baseline characteristics (intention-to-treat
population)
Characteristics
Olanzapine
(n = 49)
Haloperidol
(n = 49)
Mean age, years (SD) 69.9 (9.3) 68.4 (11.9)
Sex, n (%)
Male 33 (67) 35 (71)
Female 16 (33) 14 (29)
DRS-R-98a
Severity score, mean (SD) 18.1 (3.8) 17.6 (3.4)
Total score, mean (SD) 23.5 (3.9) 23.1 (3.4)
Delirium subtype, n (%)
Hyperactive 16 (33) 20 (41)
Hypoactive 10 (20) 17 (35)
Mixed 21 (43) 12 (24)
Unspecified 2 (4) 0 (0)
Use of opioids, n (%) 33 (67) 35 (71)
Use of benzodiazepines, n (%) 18 (37) 21 (43)
Use of neuropathic pain
medication, n (%)
7 (14) 11 (22)
Use of psychotropic medication,
n (%)
3 (6) 4 (8)
Precipitating factors,b median
(IQR; range)
2 (1-3; 0-5) 2 (1-3; 0-5)
Admission type, n (%)
Hospital 45 (92) 43 (88)
Hospice 4 (8) 6 (12)
Reason for admission, n (%)
Emergency 41 (84) 42 (86)
Scheduled 8 (16) 7 (14)
aDelirium Rating Scale-Revised-98.
bPrecipitating factors included: change in dose or type of opioids
(<48 hours before diagnosis of delirium); dehydration; infection;
intracranial malignancy; infection; metabolic imbalances.
Abbreviation: IQR, interquartile range.
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olanzapine in DRR for hyperactive, hypoactive, or mixed sub-
types (Table 2).
Futility analysis was conducted, and at this time, the condi-
tional powerwas 8.6%. As the conditional powerwas lower than
the threshold for futility, this analysis indicated that this study
was unlikely to reach the predefined efficacy criteria. Therefore,
recruitment was terminated prematurely (June 15, 2016).
Safety
TRAEs were in line with previous data [9], with TRAEs of any
grade occurring in 13 patients (26.5%) in the olanzapine arm and
16 patients (32.7%) in the haloperidol arm (Table 3). Grade ≥3
TRAEs (all leading to drug discontinuation) were reported in five
patients (10.2%) in the olanzapine arm and 10 patients (20.4%)
in the haloperidol arm (OR, 0.4; 95% CI, 0.1–1.4; p = .16). Seda-
tion was the most reported grade ≥3 TRAE, in five (10.2%) and
seven (14.3%) patients in the olanzapine and haloperidol arms,
respectively. Grade ≥3 EPS (including tremors and muscle stiff-
ness) occurred in two patients in the haloperidol arm; there was
no reported grade ≥3 EPS in the olanzapine arm. One patient in
the haloperidol arm experienced QTc prolongation (>500 msec),
and none in the olanzapine arm. All grade ≥3 TRAEs occurred on
day 1 or 2. There were no treatment-related deaths in both
treatment arms.
Delirium-Related Distress
Sixteen patients in each treatment arm completed the DEQ.
Mean delirium-related distress level (on a 0–4 numerical
rating scale) was 2.1 (SD 1.4) in the olanzapine arm and 2.3
(SD 1.4) in the haloperidol arm. The mean delirium-related
distress level rated by spouses and/or caregivers was 2.7
(SD 1.1) in the haloperidol arm and 3.0 (SD 1.2) in the
olanzapine arm. Mean delirium-related distress level rated
by attending nurses was 0.9 (SD 0.9) in the haloperidol arm
and 1.1 (SD 1.1) in the olanzapine arm.
DISCUSSION
This multicenter, phase III RCT demonstrated no statistically
significant difference in efficacy between olanzapine and hal-
operidol for the treatment of delirium in hospitalized adult
1.0 Prescribed
medication for
delirium
Haloperidol
Olanzapine
Haloperidol-censored
Olanzapine-censored0.8
0.6
0.4
0.2
0.0
0 2 4
Time from randomization, days
T
T
R
 (
p
ro
b
ab
ili
ty
)
6 8
49Haloperidol
No. at risk
Olanzapine
32 22 22 21
49 35 27 27 27
10
Gehan-Breslow-Wilcoxon test, p = .20
Figure 2. Kaplan-Meier estimates of time to response (TTR) according to treatment arm.
Table 2. Delirium Resolution Rate (DRR) for delirium motor
subtypes (intention-to-treat population)
DRR
Motor subtypea
Olanzapine
(n = 49)
Haloperidol
(n = 49)
OR, 95% CI
(p valuea)
Hyperactive, n 16 20 0.5, 0.1–2.1 (.50)
Responders,
n (%)
8 (50) 13 (65)
Hypoactive, n 10 17 0.2, 0.04–1.5 (.12)
Responders,
n (%)
3 (30) 11 (65)
Mixed, n 21 12 1.8, 0.4–7.9 (.49)
Responders,
n (%)
10 (47) 4 (33)
Unknown, n 2 0
ap two-sided chi-square test (olanzapine vs. haloperidol).
Abbreviations: CI, confidence interval; OR, odds ratio.
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patients with advanced cancer. Treatment with olanzapine
did not result in a better DRR or shorter TTR compared with
haloperidol. This trial met criteria for early stopping due to
futility.
The management of delirium is complex because of the
considerable heterogeneity in terms of etiology and clinical
subtype [22, 23]. A number of brain neural networks and
pathways have been implicated, but underlying pathophysi-
ological mechanisms remain poorly understood [24, 25].
The complexity of delirium suggests that a variety of inter-
ventions is most likely needed, which combines both
nonpharmacological and pharmacological strategies, as appro-
priate to the cancer trajectory and goals of care. The question
remains whether antipsychotic drugs are clinically useful and
safe for the treatment of delirium in patients with advanced
cancer. If so, are atypical antipsychotics preferred because of
their possibly better adverse effect profile and efficacy advan-
tages in some patients?
Collective data remain limited on the activity and safety of
antipsychotic drugs for the treatment of delirium in patients
with advanced cancer. A recently performed Cochrane review
on antipsychotics for treatment of delirium in hospitalized non-
ICU patients [9] included three studies comparing typical to
atypical antipsychotics for the treatment of delirium in patients
with advanced cancer [13–15]. Lin et al. (n = 30; 100% with a
cancer diagnosis) performed a single-center, open RCT, and
compared the efficacy between haloperidol and olanzapine to
treat delirium (DSM-IV criteria) in palliative and hospice center
patients with cancer [13]. Comparison of the scores of Delirium
Rating Scale-Chinese and Clinical Global Impression-Severity
between two groups showed no statistical difference. The study
by Maneeton et al. (n = 52; 38.5% with cancer diagnosis) was a
single-center, prospective, double-blind RCT which compared
quetiapine versus haloperidol for the treatment of delirium
(DSM-IV-TR and confusion assessment method criteria) [14].
The primary outcome measure was the DRS-R-98. They con-
cluded that low-dose quetiapine and haloperidol were equally
effective and safe.
The 2018 European Society for Medical Oncology clinical
practice guideline on delirium in adult cancer patients [8]
identified 15 studies, including three RCTs [15, 26, 27]. Kim
et al. (n = 32; 72% with a cancer diagnosis) compared ris-
peridone with olanzapine over a 7-day period [26]. The pri-
mary outcome measure was the DRS-R-98. There was no
significant difference in either efficacy or adverse effects in
this underpowered study. The second study by Hui et al.
(n = 90; 100% with a cancer diagnosis) was a single-center,
double-blind, parallel group RCT conducted in adult patients
with advanced cancer, comparing the effect of lorazepam
versus placebo as an adjuvant to haloperidol for persistent
agitation (Richmond Agitation-Sedation Scale [RASS] score
of ≥ + 2) in patients with delirium (DSM-IV-TR criteria) [27].
This study was designed to assess a different primary
research objective than our RCT.
Recently, Agar et al. [15] conducted a three-armed, multi-
center, placebo-controlled study of antipsychotic treatment of
delirium in patients receiving palliative care (n = 247, 88%
with a cancer diagnosis). Treatment with either risperidone or
haloperidol was associated with significantly greater delirium
symptom severity scores and mean extrapyramidal effects
than placebo. There was no comparison of haloperidol versus
risperidone in the Agar study. As a secondary outcome, halo-
peridol treatment was associated with poorer overall survival
in long-term follow-up. However, there are some consider-
ations that need to be addressed. First, although the thera-
peutic dose of haloperidol and the optimal dose titration
schedule for delirium remain to be defined, starting and main-
tenance doses of haloperidol for patients >65 years of age
(0.25 mg PO b.i.d., increased to a maximum of 2 mg per day)
used in the Agar study were low compared with doses
reported in previous studies in the oncology and palliative
care setting [28]. This may have underestimated the clinical
effect of antipsychotic drugs to treat delirium in patients with
advanced cancer. Furthermore, differences at baseline
between the haloperidol and placebo arms in number of
patients aged >65 years (90% vs. 80%, respectively) and the
median dose of opioids (33 vs. 15 mg, respectively) are factors
that may have affected study results. Other possible factors
impacting on study results in the Agar study are older age and
dementia or cognitive impairment, which are predictors of
poor response to antipsychotics in the treatment of delirium
[20, 29–32]. In the study by Agar et al., mean age of the
patients in the haloperidol arm was 76.5 years (21% diag-
nosed with cognitive impairment), and in the risperidone arm
mean age was 74.5 years (22% with cognitive impairment).
Median IQCODE (a structured questionnaire to detect individ-
uals who may go on to develop dementia) scores for cognitive
impairment were ≥ 4, which shows that long-term decline of
cognitive status was highly prevalent. In our study, mean age
was <70 years in both treatment arms, and patients with
Table 3. Incidence of therapy-related adverse events (intention-to-treat population)
Adverse event
Haloperidol (n = 49) Olanzapine (n = 49)
Any grade Grade 3 Grade 4/5 Any grade Grade 3 Grade 4/5a
All TRAEs, n (%) 16 (32.7) 10 (20.4) 0 13 (26.5) 4 (8.2) 1 (2.0)
Sedation, n (%) 10 (20.4) 7 (14.3) 0 9 (18.4) 4 (8.2) 1 (2.0)
EPS
Tremors, n (%) 3 (6.1) 1 (2.0) 0 2 (4.1) 0 0
Muscle stiffness, n (%) 2 (4.1) 1 (2.0) 0 1 (2.0) 0 0
Dizziness, n (%) 0 0 0 1 (2.0) 0 0
QTc prolongation, n (%) 1 (2.0) 1 (2.0) 0 0 0 0
aGrade 5 TRAEs did not occur in both treatment arms.
Abbreviations: EPS, extrapyramidal symptom; TRAE, therapy-related adverse event.
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dementia were excluded. To conclude, prescribing of antipsy-
chotic drugs for patients with delirium remains a matter of
debate [33]. Future studies need to identify baseline factors
indicating which patients will benefit most from upfront treat-
ment with antipsychotic drugs.
Overall, the safety profiles of haloperidol and olanzapine
in the dose range tested were in line with previous studies
in non-ICU patients with delirium [9]. TRAEs of any grade
occurred in 32.7% and 26.5% of the patients in the haloper-
idol and olanzapine arm, respectively. TRAEs grade ≥3 (all
leading to drug discontinuation) were reported more fre-
quently in the haloperidol arm: 20.4% versus 10.2% in the
olanzapine arm; however, this difference was not statisti-
cally significant. The most common grade ≥3 TRAE was
sedation in both treatment arms. EPS grade ≥3 was uncom-
mon, occurring in 4% of the patients in the haloperidol
arm. Only three patients in the olanzapine arm experi-
enced low grade EPS; EPS grade ≥3 did not occur in the
olanzapine arm. All TRAEs resolved without sequelae when
the study drug was discontinued. The use of antipsychotics
is associated with QTc prolongation, which can lead to life-
threatening arrhythmia [34–36]. In this study with routine
ECG assessment, only one atrioventricular block episode
was reported in the haloperidol arm.
Previous reports indicate high levels of delirium-related
distress in patients and their caregivers [5–7]. In our study,
exploratory analysis showed that mean stress scores reported
by patients were just above 2 (on a 4-point rating scale) in
both treatment arms. As expected, stress scores reported
by spouses and caregivers were high: 2.7 versus 3.0 in the hal-
operidol and olanzapine arm, respectively. Scores reported
by attending nurses were low in both treatment arms. This
could be the effect of improved professional education, pro-
viding nurses with educational resources and opportunities to
apply knowledge with regard to delirium, which increases con-
fidence in identification and management of delirium [37, 38].
This study has some limitations. First, our study did not
include a placebo control group. The absence of a comparative
placebo control group with active treatment groups limits the
interpretation of our findings. Second, the DOS was completed
not on a daily basis but at fixed times twice-weekly, or when-
ever delirium was suspected. Daily assessments were not feasi-
ble given the high workload of the nursing staff. Consequently,
some delirious cases may have remained undetected. Third,
although the rater of the DRS-R-98 scores was blinded to the
study drug, because the rater knew that all subjects were
receiving active treatment, DRS-R-98 ratings could have been
affected. Fourth, nonpharmacological interventions for the pre-
vention and treatment of delirium were not standardized across
the participating five sites in this study. However, it should be
noted that for most nonpharmacological interventions, there is
limited research evidence on which to base clinical recommen-
dations. Interventions based on the Hospital Elder Life Program
[39] have been successfully implemented in all Dutch health
care institutions. Fifth, the decision of stopping this trial early
for futility was adopted as a consequence of the results of the
interim analysis, which demonstrated that it was highly unlikely
that the trial would meet its primary objective of demonstrating
superiority of olanzapine over haloperidol. With a probability
rate of 8.6% to achieve its primary objective, this was well
below the threshold of 10% for futility. Consequently, the num-
ber of included patients is relatively small, and the power of
the analyses performed to assess secondary endpoints is low.
Finally, the use of rescue interventions to manage agitation
(e.g., benzodiazepines and physical restraints) was not prospec-
tively recorded. Because these interventions are known to be
associated with delirium, this could have introduced bias. How-
ever, it should be noted that retrospective analysis of the medi-
cal records showed that only very few patients (<3%) received
benzodiazepines, and none received physical restraints.
CONCLUSION
The atypical antipsychotic olanzapine and haloperidol were
equally effective and safe for the management of delirium in
a broad population of hospitalized patients with advanced
cancer. The focus of future placebo-controlled RCTs should
change to individualized, multimodal intervention strategies
for managing delirium.
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